Analysts at Wedbush decreased their price target on shares of Halozyme Therapeutic (NASDAQ: HALO) from $13.00 to $6.00 in a research report issued to clients and investors on Thursday. The firm currently has a “neutral” rating on the stock.
HALO has been the subject of a number of other recent research reports. Analysts at Barclays Capital reiterated an “overweight” rating on shares of Halozyme Therapeutic in a research note to investors on Friday, February 1st. They now have a $9.00 price target on the stock. Separately, analysts at BMO Capital Markets cut their price target on shares of Halozyme Therapeutic from $12.00 to $9.00 in a research note to investors on Friday, February 1st. They now have an “outperform” rating on the stock. Finally, analysts at Jefferies Group reiterated an “underperform” rating on shares of Halozyme Therapeutic in a research note to investors on Wednesday, January 30th. They now have a $4.00 price target on the stock.
Five analysts have rated the stock with a buy rating, two have issued a hold rating, and one has issued a sell rating to the company. The company has a consensus rating of “overweight” and a consensus price target of $9.14.
Halozyme Therapeutic traded up 3.22% on Thursday, hitting $5.45. Halozyme Therapeutic has a 1-year low of $3.86 and a 1-year high of $13.50. The stock’s 50-day moving average is currently $6.91. The company’s market cap is $612.2 million.
Halozyme Therapeutic last issued its quarterly earnings data on Monday, February 25th. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.16) by $0.12. The company had revenue of $21.80 million for the quarter, compared to the consensus estimate of $7.32 million. During the same quarter in the previous year, the company posted ($0.18) earnings per share. The company’s revenue for the quarter was up 808.3% on a year-over-year basis. Analysts expect that Halozyme Therapeutic will post $-0.52 EPS for the current fiscal year.
Halozyme Therapeutics, Inc. is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.